Evidence map›Paper›PMID 33615222›Full record

ArticleNeuro-oncology advances

Radiogenomic modeling predicts survival-associated prognostic groups in glioblastoma.

Nicholas Nuechterlein, Beibin Li, Abdullah Feroze, Eric C Holland, Linda Shapiro, David Haynor, James Fink, Patrick J Cimino

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nicholas NuechterleinPaul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, Washington, USA.
Beibin LiPaul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, Washington, USA.
Abdullah FerozeDepartment of Neurological Surgery, University of Washington, Seattle, Washington, USA.
Eric C HollandDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Linda ShapiroPaul G. Allen School of Computer Science & Engineering, University of Washington, Seattle, Washington, USA.
David HaynorDepartment of Radiology, University of Washington, Seattle, Washington, USA.
James FinkDepartment of Radiology, University of Washington, Seattle, Washington, USA.
Patrick J CiminoDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Funding

CHARACTERIZING AGGRESSIVE GLIOMA COPY NUMBER SUBTYPESK08CA245037 · NCI · UNIVERSITY OF WASHINGTON · PI CIMINO, PATRICK J. · 2020 to 2021
$512k
NCI NIH HHS K08 CA245037
6 · The paper itself

Abstract

backgroundCombined whole-exome sequencing (WES) and somatic copy number alteration (SCNA) information can separate

methodsRadiologic features (

resultsWe were able to classify glioblastomas into two prognostic subgroups with a cross-validated area under the curve score of 0.80 (±0.03) using ridge logistic regression on the 15-dimensional principle component analysis (PCA) embedding of the features selected by our novel feature selection method. An interrogation of the selected features suggested that features describing contours in the T2 signal abnormality region on the T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI sequence may best distinguish these two groups from one another.

conclusionsWe successfully trained a machine learning model that allows for relevant targeted feature extraction from standard MRI to accurately predict molecularly-defined risk-stratifying

Indexed as

biomarkerscopy number alterationsglioblastomaMRIradiogenomics

Identifiers

PMID33615222
PMCPMC7883769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.